Chemical

FMC to sell Newark property in $114 million deal & lease back key research site

The company said it will retain ownership of adjacent Maryland properties and emphasized that the deal is intended to optimize its asset base

  • By ICN Bureau | June 24, 2026
FMC Corporation has agreed to a framework deal to sell its Newark, Delaware property for approximately $114 million, in a move designed to unlock capital while keeping its core operations firmly in place.
 
The transaction remains subject to due diligence, regulatory approvals, and other closing conditions, with completion expected in the fourth quarter of 2026. Under the proposed structure, FMC would sell the property and lease back the facilities it currently operates.
 
The company said it will retain ownership of adjacent Maryland properties and emphasized that the deal is intended to optimize its asset base, converting underutilized real estate into capital for debt reduction without disrupting its operational footprint.
 
At the heart of the site is FMC’s Stine Research Center, the company’s global R&D headquarters, which will continue to operate following the transaction. FMC stressed that its research capabilities and scientific infrastructure will remain fully in place.
 
"The Stine Research Center remains the global headquarters for FMC's R&D organization and will continue to play a central role in advancing our innovation pipeline,” said Seva Rostovtsev, executive vice president and chief technology officer. 
 
“This transaction allows us to optimize our physical footprint by reducing underutilized space while preserving and improving the world-class facilities, infrastructure and scientific talent that power our research and long-term growth.”
 
“Unlocking the value of underutilized real estate and applying the proceeds to debt reduction reflects our ongoing commitment to strengthening our balance sheet without compromising the investments and capabilities that will drive FMC's future growth,” said Andrew Sandifer, executive vice president and chief financial officer.

Upcoming Conferences

ChemPharma R&D Summit 2026

October 27, 2026

Other Related stories

Startups

Petrochemical

Energy

Digitization